Amicus Therapeutics Inc. (FOLD) Plunges 9.98%

Amicus Therapeutics Inc. (FOLD) Plunges 9.98%

Amicus Therapeutics Inc. (FOLD) had a rough trading day for Friday October 04 as shares tumbled 9.98%, or a loss of $-0.87 per share, to close at $7.85. After opening the day at $8.69, shares of Amicus Therapeutics Inc. traded as high as $8.73 and as low as $7.79. Volume was 5.38 million shares over 25,713 trades, against an average daily volume of n/a shares and a total float of 254.63 million.

As a result of the decline, Amicus Therapeutics Inc. now has a market cap of $2 billion. In the last year, shares of Amicus Therapeutics Inc. have traded between a range of $14.62 and $7.11, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.

Amicus Therapeutics Inc is a global biotechnology company that aims to treat rare and orphan diseases. The company’s strategy focuses on global capacity with an international infrastructure, late-stage product acquisition, and biologics manufacturing. Amicus leverages its pharmacological technology to develop treatments for human genetic diseases by targeting mutated proteins. The company utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products.

Amicus Therapeutics Inc. is based out of Cranbury, NJ and has some 508 employees. Its CEO is John F. Crowley.

Amicus Therapeutics Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

error: Content is protected !!